U.S. Imposes 100% Tariffs on Patented Pharmaceuticals Unless Firms Strike Deals with HHS

U.S. Imposes 100% Tariffs on Patented Pharmaceuticals Unless Firms Strike Deals with HHS

The U.S. government has implemented a 100% tariff on patented pharmaceutical imports, effective July 31, 2026, for large manufacturers and September 29, 2026, for smaller firms, unless companies secure agreements with the Department of Health and Human Services (HHS). This policy, authorized under Section 232 of the Trade Expansion Act of 1962, follows a Commerce Department report highlighting vulnerabilities in the nation’s pharmaceutical supply chain. As of 2025, 53% of patented pharmaceuticals distributed domestically were produced abroad, with only 15% of active pharmaceutical ingredients (APIs) manufactured in the U.S. The administration cited foreign government interventions and supply chain disruptions, including those linked to the 2025 Supreme Court ruling, as justification for the measure. The policy aims to secure critical medical supplies for civilian and military use, with a focus on patented drugs essential for treating cancer, rare diseases, and infectious pathogens. Generic pharmaceuticals and biosimilars remain exempt, aligning with broader trade strategies targeting steel, copper, and aluminum imports.

Tariff Structure and Exemptions

The tariff structure includes a tiered system of duties, with patented pharmaceuticals and their ingredients listed in Annex I facing a 100% ad valorem duty. Companies agreeing to MFN pricing deals or committing to onshoring production can reduce tariffs to 20%, with the rate increasing to 100% by April 2, 2030. Onshoring commitments require domestic manufacturing facilities to be operational by January 20, 2029. Trade partners such as the European Union, Japan, South Korea, Switzerland, and Liechtenstein face lower tariffs—15% for most and 10% for the UK—under existing trade agreements. The Strategic API Reserve exemption applies to certain specialty pharmaceuticals, including orphan drugs and medical countermeasures, provided they meet urgent U.S. health needs or are produced in jurisdictions with trade/security agreements. Generic pharmaceuticals and their ingredients are excluded from immediate adjustments, though the administration reserves the right to reassess exemptions annually.

Industry Responses and Compliance Challenges

Over a dozen major pharmaceutical companies have signed agreements with the Trump administration to avoid levies, including Pfizer, Merck, and Novo Nordisk. These MFN pricing deals involve negotiated pricing structures for U.S. consumers and are not directly tied to direct sales mechanisms. The administration estimates $400 billion in reshoring pledges from these agreements, aligning with the TrumpRx initiative to stabilize drug costs. However, critics note that many targeted medications have cheaper generic alternatives. Firms without agreements face 100% tariffs, creating financial pressure, particularly for smaller manufacturers. The administration has provided a 120-day implementation window for large companies and 180 days for smaller ones, though compliance with onshoring requirements remains challenging due to high capital investment and regulatory hurdles. The Department of Commerce mandates periodic reporting and audits of onshoring plans, adding administrative complexity.

Broader Trade Strategy and Economic Impact

The policy is projected to generate $70 billion in federal income over 10 years from adjusted duties on steel, copper, and aluminum imports. While pharmaceutical tariffs are not directly tied to this figure, the broader trade strategy aims to reduce reliance on foreign materials for drug production. The 50% duty on steel, copper, and aluminum imports, based on U.S. customer prices rather than seller-assigned values, reflects efforts to address undervaluation of exports and stabilize domestic industries. Strategically, the policy seeks to enhance U.S. self-sufficiency in critical medications by incentivizing domestic manufacturing of patented drugs, which are vital for public health and national defense. The administration argues that increased domestic production will mitigate vulnerabilities in global supply chain disruptions, such as those during the 2025 pandemic. However, critics warn that tariffs could raise drug prices for consumers, particularly for medications not covered by the TrumpRx pricing deals. The Department of Health and Human Services acknowledges affordability concerns but maintains that long-term benefits of domestic production outweigh short-term costs.

Legal and Operational Challenges

The implementation of the pharmaceutical tariffs faces legal and operational challenges. The Supreme Court’s 2025 ruling invalidating some of Trump’s earlier tariffs has raised questions about the legality of the current policy, though the administration asserts it falls under Section 232’s national security provisions. Compliance with onshoring requirements may be difficult for smaller firms lacking capital to restructure operations, potentially leading to market consolidation or reduced competition. Critics, including industry analysts and advocacy groups, argue that the tariffs could exacerbate affordability issues for patients, particularly for medications not covered by the TrumpRx deals. While the administration claims most products will see lower prices due to revised tariff calculations, others warn that the 100% duty could drive up costs for branded drugs. The exclusion of generic pharmaceuticals from immediate tariffs has drawn scrutiny, as these medications account for a significant portion of the U.S. market. The administration defends the decision, stating generics are less critical for national security and their exclusion allows targeted support for patented medications. Nonetheless, the policy’s long-term impact on healthcare access and pharmaceutical innovation remains a subject of ongoing debate.